Patents Assigned to College
  • Concentrated aqueous silk fibroin solution and use thereof
    Patent number: 9084840
    Abstract: The present invention provides for concentrated aqueous silk fibroin solutions and an all-aqueous mode for preparation of concentrated aqueous fibroin solutions that avoids the use of organic solvents, direct additives, or harsh chemicals. The invention further provides for the use of these solutions in production of materials, e.g., fibers, films, foams, meshes, scaffolds and hydrogels.
    Type: Grant
    Filed: April 17, 2009
    Date of Patent: July 21, 2015
    Assignee: Trustees of Tufts College
    Inventors: David L. Kaplan, Ung-Jin Kim, Jaehyung Park, Hyoung-Joon Jin
  • Methods for diagnosing and treating neuroendocrine cancer
    Patent number: 9084775
    Abstract: The present invention relates to a method for diagnosing neuroendocrine cancers via detecting the presence of N-methyl D-asparate-associated (NMDA) glutamate receptors type 1 and/or type 2. Methods for preventing and treating neuroendocrine cancers are also disclosed.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: July 21, 2015
    Assignee: Trustees of Dartmouth College
    Inventor: William G. North
  • Single Agent Anti-PD-L1 and PD-L2 Dual Binding Antibodies and Methods of Use
    Publication number: 20150197571
    Abstract: The present invention is based, in part, on the identification of novel antibodies that have binding affinity for both PD-L1 and PD-L2 and methods of using same. In one aspect, an isolated monoclonal antibody, or antigen-binding fragment thereof, which specifically binds both PD-L1 and PD-L2, is provided. In one embodiment, both PD-L1 and PD-L2 are human PD-L1 and human PD-L2.
    Type: Application
    Filed: August 2, 2013
    Publication date: July 16, 2015
    Applicants: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Arlene H. Sharpe
  • METHOD FOR DETERMINING SENSITIVITY TO DECITABINE TREATMENT
    Publication number: 20150197813
    Abstract: The present invention is a gene expression panel of chemotherapeutic drug-resistant cancer stem cells comprising RIN1, SOX15 and TLR4. In one embodiment the cancer stem cells are testicular cancer germ cells. The present invention provides for a kit and method for determining response to treatment with decitabine at low doses.
    Type: Application
    Filed: July 31, 2013
    Publication date: July 16, 2015
    Applicant: Trustees of Dartmouth College
    Inventors: Michael Spinella, Maroun J. Beyrouthy
  • USE OF NANOWIRES FOR DELIVERING BIOLOGICAL EFFECTORS INTO IMMUNE CELLS
    Publication number: 20150197807
    Abstract: The present invention generally relates to nanowires and, in some aspects, to methods of using nanowire arrays to identify a therapeutic target for treating a disorder in a subject, identify a treatment for a disorder in a subject, or deliver a biological effector to immune cells. Previous techniques for delivering biological effectors into live immune cells yielded low efficiencies, activated the immune response and induced non-specific inflammation, and/or required harsh conditions that resulted in widespread apoptosis. By contrast, some of the methods described herein are capable of efficiently delivering biomolecular cargo into immune cells, have negligible toxicity, do not activate immune cell function, and/or allow cells to respond appropriately to physiological stimuli.
    Type: Application
    Filed: March 15, 2013
    Publication date: July 16, 2015
    Applicant: Presidents and Fellows of Harvard College
    Inventors: Hongkun Park, Alexander K. Shalek, Jellert T. Gaublomme
  • Process for preparing silica microparticles
    Patent number: 9080056
    Abstract: Silica core-shell microparticles are prepared by growing a porous silica shell from a silica precursor onto the surface of non-porous silica particle dispersed in a mixed surfactant solution under basic pH conditions. The particles are hydrothermally treating in an oil-in-water emulsion system and the particles are calcined to remove residual surfactants. Optionally, the particles of may be base etched to expand the size of the pores in the silica shell. Core-shell silica particles with an ordered mesoporous layer are produced.
    Type: Grant
    Filed: November 26, 2009
    Date of Patent: July 14, 2015
    Assignee: University College Cork—National University of Ireland, Cork
    Inventors: Jeremy D. Glennon, Jesse Omamogho
  • Compositions for the treatment of addiction, psychiatric disorders, and neurodegenerative disease
    Patent number: 9078886
    Abstract: The present invention features, inter alia, pharmaceutically acceptable compositions that include metyrapol as the sole pharmaceutically active agent; compositions that include metyrapol and at least one additional pharmaceutically active agent; compositions in which the agent targeting the HPA axis is, itself, new or modified (e.g., a bi-specific antibody designed to traverse the blood-brain barrier or a known compound redesigned by, for example, conjugation to a substance that traverses the blood-brain barrier); and compositions in which the agent targeting the HPA axis is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to include a dosage that is too low to reduce plasma cortisol levels or formulated to preferentially affect the skin.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: July 14, 2015
    Assignees: Embera Neurotherapeutics, Inc., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Nicholas E. Goeders, Barbara S. Fox, Glenn Guerin
  • Methods for increasing plasmin activity and promoting plaque regression in the treatment of atherosclerosis
    Patent number: 9078904
    Abstract: The present invention provides the use of recombinant plasminogen activator inhibitor-1 (PAI-1) isoform 23 in methods of increasing plasmin activity, inhibiting angiogenic vasa vasorum, promoting plaque regression and treating atherosclerosis by administering to a subject in need of treatment an effective amount of recombinant plasminogen activator inhibitor type isoform 23 (rPAI-123). In some embodiments, rPAI-123 is set forth in SEQ ID NOs:5-8. In other embodiments, rPAI-123 is administered at a dose in the range of approximately 2.5 ?g/kg/day to 20 ?g/kg/day. In further embodiments, the effective amount achieves a ratio of rPAI-123 to PAI-1 is in the range of approximately 1:2 to 3:1.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: July 14, 2015
    Assignee: Trustees of Dartmouth College
    Inventor: Mary Jo Mulligan-Kehoe
  • Methods of modulation of branched chain acids and uses thereof
    Patent number: 9078865
    Abstract: A method of modulating plasma levels of branched chain amino acids and branched chain alpha-keto acids is disclosed, wherein an ammonia scavenger compound or a salt thereof, for example phenylbutyrate or an even numbered congener thereof or a salt thereof, is administered to an individual in need thereof. In various methods, a decrease in plasma levels of branched chain amino acids and branched chain alpha-keto acids is effected to treat individuals suffering from an inborn error in metabolism of amino acids, such as Maple Syrup Urine Disease, for example.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: July 14, 2015
    Assignee: Baylor College of Medicine
    Inventor: Brendan Lee
  • Highly -selective olefins metathesis
    Patent number: 9079173
    Abstract: The present invention relates generally to catalysts and processes for the Z-selective formation of internal olefin(s) from terminal olefin(s) via homo-metathesis reactions.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: July 14, 2015
    Assignees: Massachusetts Institute of Technology, Trustee of Boston College
    Inventors: Richard R. Schrock, Annie J. King, Yu Zhao, Margaret M. Flook, Amir H. Hoveyda
  • Method for delivering agents into cells using bacterial toxins
    Patent number: 9079952
    Abstract: The invention provides compositions and methods for delivering a bioactive moiety comprising at least one non-natural component into a cell cytosol of an eukaryotic cell. The bioactive moiety is linked to an A component of a bacterial toxin, a functional wild-type or modified fragment thereof, or an A component surrogate or mimetic. For delivery, the cell is contacted with the linked bioactive moiety and a corresponding B component of the bacterial toxin or a functional fragment thereof.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: July 14, 2015
    Assignee: President and Fellows of Harvard College
    Inventors: Robert J. Collier, Brad L. Pentelute
  • THERAPEUTICS DISPENSING DEVICE AND METHODS OF MAKING SAME
    Publication number: 20150190279
    Abstract: A therapeutics delivery system, and methods of making and using same, are disclosed for environments that rapidly clear any injected therapeutics, such as a patient's eye. The therapeutics delivery system releases the drug in a therapeutically effective concentration for a desired duration of time with a predefined drug kinetics. In one embodiment, the embodiments of the present disclosure release a therapeutically effective concentration for a longer time period than other delivery systems, for instance from a day to a week. Certain embodiments comprise a therapeutics dispensing device comprising a biodissolvable hydrogel matrix for long term drug release that allows the device to be placed directly at the injured site, e.g., onto the surface at or near the injury, and retained there rather than through injection, whether locally or systematically.
    Type: Application
    Filed: August 6, 2013
    Publication date: July 9, 2015
    Applicant: Baylor College of Medicine
    Inventors: Ghanashyam Acharya, Stephen C. Pflugfelder, Cintia S. De Paiva, Jennifer L. Simpson
  • MODULATION OF UBE3A-ATS EXPRESSION
    Publication number: 20150191723
    Abstract: Certain embodiments are directed to methods and compounds for inhibiting UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A). Such methods and compounds are useful for inducing expression of paternal UBE3A in cells and animals.
    Type: Application
    Filed: June 25, 2013
    Publication date: July 9, 2015
    Applicants: Baylor College of Medicine, Isis Pharmaceuticals, Inc.
    Inventors: Frank Rigo, Amanda Ward, Linyan Meng, Arthur L. Beaudet
  • Natural composition to decrease effects of a high fat diet
    Patent number: 9072762
    Abstract: The combination of gallic acid, ellagic acid, and rubusoside was shown to inhibit angiogenesis by inhibition of pro-angiogenic factors. These three compounds were shown to be absorbed from the intestine making the compounds orally bioavailable. The ratio of the three compounds in the composition was a weight ratio of approximately 1:1.7:17.0 of gallic acid, ellagic acid, and rubusoside, respectively, resulting in a composition with 5% w/w gallic acid, 9% w/w ellagic acid, and 86% w/w rubusoside. This combination was also shown to reduce weight gain, fat accumulation, and serum cholesterol in mammals fed a high fat diet. It also reduced serum triglycerides and tended to reduce blood glucose in mammals on both normal and high fat diets. This three-compound composition (“GER”) can be used to treat diseases associated with angiogenesis and to decrease effects of a high fat diet.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: July 7, 2015
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Zhijun Liu, Peiying Yang
  • Cell-based detection of APF through its interaction with CKAP4 for diagnosis of interstitial cystitis
    Patent number: 9075045
    Abstract: An assay system designed to detect a protein biomarker in urine that is diagnostic for interstitial cystitis (IC). The presence of a 9 amino acid glycopeptide, antiproliferative factor (APF), in urine is unique to patients with IC. Urine samples from patients who exhibit symptoms consistent with IC are added to the assay system. Binding of APF to the cytoskeletal associated protein 4 (CKAP4) is positive for the presence of APF in urine and diagnostic for IC. The diagnostic system is a significant and surprising advance in diagnosis of IC and has commercial applications relevant to women and men who suffer from symptoms consistent with IC.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: July 7, 2015
    Assignees: The Commonwealth Medical College, University of Florida Research Foundation, Inc.
    Inventors: David Alan Zacharias, Sonia Lobo Planey
  • Motion tracking system for real time adaptive imaging and spectroscopy
    Patent number: 9076212
    Abstract: This invention relates to a system that adaptively compensates for subject motion in real-time in an imaging system. An object orientation marker (30), preferably a retro-grate reflector (RGR), is placed on the head or other body organ of interest of a patient (P) during a scan, such as an MRI scan. The marker (30) makes it possible to measure the six degrees of freedom (x, y, and z-translations, and pitch, yaw, and roll), or “pose”, required to track motion of the organ of interest. A detector, preferably a camera (40), observes the marker (30) and continuously extracts its pose. The pose from the camera (40) is sent to the scanner (120) via an RGR processing computer (50) and a scanner control and processing computer (100), allowing for continuous correction of scan planes and position (in real-time) for motion of the patient (P).
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: July 7, 2015
    Assignees: The Queen's Medical Center, The University of Hawaii, The Medical College of Wisconsin, Inc., UWM Research Foundation, Inc.
    Inventors: Thomas Michael Ernst, Thomas Edmund Prieto, Brian Stewart Randall Armstrong
  • Mutant Cas9 proteins
    Patent number: 9074199
    Abstract: Methods of making mutant Cas9 proteins are described.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: July 7, 2015
    Assignee: President and Fellows of Harvard College
    Inventors: Alejandro Chavez, Frank Poelwijk, George M. Church
  • Stabilized MAML peptides and uses thereof
    Patent number: 9074009
    Abstract: Stably cross-linked a polypeptides related to human MAML are described. These cross-linked polypeptides contain at least two modified amino acids that together form an internal cross-link or tether that can help to stabilize the alpha-helical secondary structure that is thought to be important for binding of MAML peptides to the Notch transcription complex, a complex that includes ICN and CSL.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: July 7, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: James Bradner, Raymond Moellering, Gregory L. Verdine
  • -selective ring-closing metathesis reactions
    Patent number: 9073801
    Abstract: The present invention relates generally to olefin metathesis. In some embodiments, the present invention provides methods for Z-selective ring-closing metathesis.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: July 7, 2015
    Assignees: Massachusetts Institute of Technology, Trustees of Boston College
    Inventors: Amir H. Hoveyda, Miao Yu, Chenbo Wang, Richard R. Schrock
  • Synthesis of tetracyclines and intermediates thereto
    Patent number: 9073829
    Abstract: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously thought susceptible to tetracycline antibiotics. The recent development of a modular synthesis of tetracycline analogs through a chiral enone intermediate has allowed for the efficient synthesis of novel tetracycline analogs never prepared before. The present invention provides more efficient routes for preparing the enone intermediate and allows for substituents at positions 4a, 5, 5a, and 12a of the tetracycline ring system.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: July 7, 2015
    Assignee: President and Fellows of Harvard College
    Inventors: Andrew G. Myers, David A. Kummer, Derun Li, Evan Hecker, Amelie Dion, Peter M. Wright